Key points are not available for this paper at this time.
T cells expressing higher levels of PD1 which can be modulated by anti-PD1. These data set the scene for clinical evaluation of denosumab use in patients receiving contemporary immune checkpoint blockade.
Ahern et al. (2018) studied this question.